Intra-articular guanethidine injection for resistant shoulder pain: a preliminary double blind study of a novel approach

Kamel Gado, Paul Emery

Abstract

Objective—To study the effect of intra-articular (IA) sympathetic blockade for the relief of resistant shoulder pain.

Methods—Eighteen patients with shoulder pain resistant to conventional treatment were allocated randomly to two groups, to receive either IA guanethidine 20 mg or IA saline. They were assessed for pain, and range of active movements, before injection and at one, four, and eight weeks after injection.

Results—There were no significant differences between groups, but the group receiving guanethidine showed greater improvement in pain relief at all three follow up visits compared with those receiving placebo (9% v 7% at one week; 15% v 6% at four weeks and 36% v 16% at eight weeks). The improvement reached significance (p < 0.05) at the eight week visit compared with baseline. The range of movement was not significantly improved in either group.

Conclusion—The results suggest that IA guanethidine produced measurable improvement in resistant shoulder pain and that further studies of this novel approach are indicated.


Shoulder pain is one of the most common medical problems. In the USA, Kelsey reported in 1982 an incidence of 1 million cases in 1967. In the United Kingdom, data from the Department of Health and Social Security suggest an incidence of 1 in 170.2 Several investigators in both the United Kingdom and Scandinavia have reported a prevalence of about 20% in geriatric populations.3,4 The most common causes of shoulder pain (as a result of shoulder disease) are rheumatoid arthritis (RA), frozen shoulder, rotator cuff tendinitis, and osteoarthritis (OA). Although conventional treatment, which includes intra-articular (IA) injections of steroid, physiotherapy, suprascapular nerve block5,6 and various other forms of pain relief modalities, is effective in the majority of patients, a painful stiff shoulder remains a common cause of prolonged disability for many patients.

Considerable interest has been shown in the role of the sympathetic nervous system (SNS) in musculoskeletal pain transmission in the pathogenesis of inflammation. Studies have shown that substances blocking the SNS (namely guanethidine and reserpine) were able to reduce inflammation and joint injury in animals in an experimental model of arthritis7 and patients with RA.8 Sympathetic innervation of the shoulder in humans was first reported by Gardner in 1948;9 anatomical studies of animal models have provided further evidence of sympathetic innervation of the elbow and knee.10 Guanethidine is the drug used most commonly as an SNS blocker, and has been shown to deplete peripheral stores of catecholamines.8 Intravenous (IV) guanethidine, used regionally, has been shown to achieve measurable pain relief and an increase in pinch strength.10 In 1992, Butler-Manuel et al used scintigraphy to show that anterior knee pain was sympathetically mediated, and they provided both subjective and objective evidence of improvement after lumbar sympathetic blockade.11 Reflex sympathetic dystrophy of either shoulder or knee joints is another well known example of the relationship of SNS and chronic pain syndromes.12 Regional sympathetic blockade using guanethidine is now a standard treatment in pain clinics for cases of reflex sympathetic dystrophy of the lower limbs.13

It is possible that at least a component of chronic shoulder pain is sympathetically mediated. The aim of this study was to investigate the efficacy of a new route of injection of guanethidine (namely IA), in alleviating shoulder pain resistant to other treatments.

Patients and methods

PATIENT POPULATION

The study was approved by the South Birmingham Health Authority Ethical Committee. Eighteen patients who agreed to participate in the study and gave informed consent were recruited from the shoulder clinics of Queen Elizabeth and Selly Oak Hospitals, Birmingham, United Kingdom. They comprised six patients with RA (American College of Rheumatology criteria14), five patients with OA (diagnosed according to both clinical and radiological criteria), five patients with frozen shoulder (according to the Cyriax criteria15—that is, painful limitation of all shoulder movement with external rotation of less than 50%), one patient with rotator cuff tendinitis that was diagnosed by painful limitation of active abduction with positive
painful arc sign, and one patient with psoriatic arthritis diagnosed clinically.

All patients suffered from persistent joint pain on movement with or without rest pain and had failed the standard shoulder protocol which included sequential treatment with an IA steroid (given subacromially and posteriorly), followed by suprascapular nerve block and physiotherapy. All patients had received a nerve block in the previous three months. Patients with fractures, dislocation of the humerus or cervical spondylosis were excluded, as were those with any sensory symptoms or signs in the affected arm, or radiation of pain to the neck. All patients were receiving analgesics, all patients except those with OA were also receiving anti-inflammatory drugs, and patients with RA were also taking disease modifying medication. No alteration of the dose of medication was allowed during the period of study.

EXPERIMENTAL PROCEDURE
All the patients were blinded as to the treatment they received. This was selected from preshuffled randomisation cards by the shoulder clinic nurse who filled the syringe. Patients received either 20 mg guanethidine (2 ml) or 0-9% saline 2 ml by the posterior IA approach. Injections and assessment were performed by a physician blind to the treatment. Patients were assessed before injection and at one, four, and eight weeks after injection. Assessments included the degree of pain on a 10 cm vertical visual analogue scale (VASP) and the range of active movements of flexion, extension, abduction, and external rotation, recorded with a goniometer. Patients were allowed to rest on a couch for one hour after the procedure. As dictated by the ethics committee, the patients who received placebo drug had the option of receiving active medication at the end of the study; six patients in the placebo group chose to do this and were reassessed at eight weeks after active injection.

STATISTICAL ANALYSIS
Statistical analysis was performed comparing the follow up values with the base line values (visit 0) using Student’s t test.

Results
No side effects were recorded during the course of study from either injections; in particular, there was no significant hypotension.

GUANETHIDINE GROUP
The diagnoses of the patients who received IA guanethidine were OA (four), RA (two), frozen shoulder (two), and psoriatic arthritis (one). For these patients, the mean reduction in VASP value at follow up was 8-9%, 15-3%, and 35-9% at the three follow up visits. The difference between follow up and baseline reached significance for the eight week visit (p < 0-05) (figure). The range of active move-
Intra-articular guanethidine for resistant shoulder pain

Intra-articular (IA) injection of guanethidine was not seen which relieved the study, the first attempt to investigate the efficacy of an IA injection of guanethidine in the relief of resistant shoulder pain, revealed that guanethidine produced a significant improvement at the two month follow up, which was not seen in the saline group. The level of improvement of VASP in the saline group was within the recognised values for placebo group (up to 30%).

It was interesting to note that significant (> 50%) improvement was also seen in four of the six patients who, having failed to respond to placebo, subsequently received IA guanethidine.

A previous study of regional IV guanethidine has shown improvement of their pain in patients with RA.

The effect of guanethidine is presumed to be mediated largely by the depletion of catecholamines from sympathetic postganglionic efferents. Reduced sympathetic outflow would decrease the direct inflammatory effect of catecholamines and the indirect catecholamine stimulation of unmyelinated peptidergic afferents implicated in the inflammatory process.

The fact that all our patients were resistant to IA steroid injection, physiotherapy, and other well known pain relief modalities, made it difficult to compare our results with other studies using the previously mentioned modalities. All patients had previously received suprascapular nerve block; we do not know whether this in some way sensitised the patients to respond to guanethidine. The observation of no significant improvement in range of movement in either group was not unexpected, as most of the patients had marked destruction of the shoulder joint radiologically.

The results achieved in this preliminary study suggest that IA guanethidine has a measurable effect in patients with resistant shoulder pain. Despite the relatively small number and heterogenous nature of the patients, a significant improvement was found in the active group and this should be considered encouraging. However, it is clear that a longer term study with a larger number of more homogenous patients is required before the value of this approach can be fully assessed.

Whether it is possible to recognise symptoms that indicate SNS involvement, or whether the earlier use of SNS blockade could be more effective, are questions which both require attention. This treatment does, however, appear to offer another option in a group of patients with limited treatment alternatives.

We thank our shoulder clinic nurse, Mrs Kathy Chiswell, for her help throughout the course of this study. This research was sponsored by a grant from the Arthritis and Rheumatism Council, United Kingdom.

K Gado and P Emery

doi: 10.1136/ard.55.3.199

Updated information and services can be found at:
http://ard.bmj.com/content/55/3/199

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/